Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut •  Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly •  Additional presentations...

Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare...

Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community Rethink Acromegaly is created by Chiesi and members of the acromegaly community to help people living with the condition, along with their caregivers and families, to make informed healthcare...

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare...

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB)FILSUVEZ was well tolerated and...